Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

Amele, S.; Peters, L.; Sluzhynska, M.; Yakovlev, A.; Scherrer, A.; Domingo, P.; Gerstoft, J.; Viard, J.P.; Gisinger, M.; Flisiak, R.; Bhaghani, S.; Ristola, M.; Leen, C.; Jablonowska, E.; Wandeler, G.; Stellbrink, H.; Falconer, K.; D'Arminio Monforte, A.; Horban, A.; Rockstroh, J.K.; Lundgren, J.D.; Mocroft, A.; Losso, M.; Kundro, M.; Schmied, B.; Zangerle, R.; Karpov, I.; Vassilenko, A.; Mitsura, V.M.; Paduto, D.; Clumeck, N.; De Wit, S.; Delforge, M.; Florence, E.; Vandekerckhove, L.; Hadziosmanovic, V.; Begovac, J.; Machala, L.; Jilich, D.; Sedlacek, D.; Kronborg, G.; Benfield, T.; Katzenstein, T.; Pedersen, C.; Johansen, I.S.; Ostergaard, L.; Wiese, L.; Moller, N.F.; Nielsen, L.N.; Zilmer, K.; Smidt, J.; Aho, I.; Girard, P.-.; Pradier, C.; Fontas, E.; Duvivier, C.; Behrens, G.; Degen, O.; Stefan, C.; Bogner, J.; Fatkenheuer, G.; Chkhartishvili, N.; Gargalianos, P.; Xylomenos, G.; Armenis, K.; Sambatakou, H.; Szlavik, J.; Gottfredsson, M.; Mulcahy, F.; Yust, I.; Turner, D.; Burke, M.; Shahar, E.; Hassoun, G.; Elinav, H.; Haouzi, M.; Elbirt, D.; Sthoeger, Z.M.; Esposito, R.; Mazeu, I.; Mussini, C.; Mazzotta, F.; Gabbuti, A.; Vullo, V.; Lichtner, M.; Zaccarelli, M.; Antinori, A.; Acinapura, R.; Plazzi, M.; Lazzarin, A.; Castagna, A.; Gianotti, N.; Galli, M.; Ridolfo, A.; Rozentale, B.; Uzdaviniene, V.; Matulionyte, R.; Staub, T.; Hemmer, R.; Reiss, P.; Reikvam, D.H.; Maeland, A.; Bruun, J.; Knysz, B.; Gasiorowski, J.; Inglot, M.; Bakowska, E.; Grzeszczuk, A.; Parczewski, M.; Maciejewska, K.; Aksak-Was, B.; Beniowski, M.; Mularska, E.; Smiatacz, T.; Gensing, M.; Kamerys, J.; Wojcik, K.; Mozer-Lisewska, I.; Caldeira, L.; Mansinho, K.; Maltez, F.; Radoi, R.; Oprea, C.; Panteleev, A.; Panteleev, O.; Trofimora, T.; Khromova, I.; Kuzovatova, E.; Borodulina, E.; Vdoushkina, E.; Jevtovic, D.; Tomazic, J.; Miro, J.M.; Laguno, M.; Martinez, E.; Garcia, F.; Blanco, J.L.; Martinez-Rebollar, M.; Mallolas, J.; Moreno, S.; Rodriguez, J.M.; Clotet, B.; Jou, A.; Paredes, R.; Tural, C.; Puig, J.; Bravo, I.; Gutierrez, M.; Mateo, G.; Sambeat, M.A.; Laporte, J.M.; Sonnerborg, A.; Treutiger, C.J.; Flamholc, L.; Weber, R.; Cavassini, M.; Calmy, A.; Furrer, H.; Battegay, M.; Schmid, P.; Kuznetsova, A.; Kyselyova, G.; Gazzard, B.; Johnson, A.M.; Simons, E.; Edwards, S.; Phillips, A.; Johnson, M.A.; Orkin, C.; Weber, J.; Scullard, G.; Clarke, A.; Rasmussen, L.D.; Svedhem, V.; Kowalska, J.D.; Guaraldi, G.; Kirk, O.; Bojesen, A.; Raben, D.; Kristensen, D.; Laut, K.; Larsen, J.F.; Podlekareva, D.; Nykjaer, B.; Cozzi-Lepri, A.; Pelchen-Matthews, A.

doi:10.1111/hiv.12711

Objectives: The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy. Methods: Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment. Results: Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of 5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%), completed HCV treatment (1598 of 3876; 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001). Conclusions: In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA / S. Amele, L. Peters, M. Sluzhynska, A. Yakovlev, A. Scherrer, P. Domingo, J. Gerstoft, J.P. Viard, M. Gisinger, R. Flisiak, S. Bhaghani, M. Ristola, C. Leen, E. Jablonowska, G. Wandeler, H. Stellbrink, K. Falconer, A. D'Arminio Monforte, A. Horban, J.K. Rockstroh, J.D. Lundgren, A. Mocroft, M. Losso, M. Kundro, B. Schmied, R. Zangerle, I. Karpov, A. Vassilenko, V.M. Mitsura, D. Paduto, N. Clumeck, S. De Wit, M. Delforge, E. Florence, L. Vandekerckhove, V. Hadziosmanovic, J. Begovac, L. Machala, D. Jilich, D. Sedlacek, G. Kronborg, T. Benfield, T. Katzenstein, C. Pedersen, I.S. Johansen, L. Ostergaard, L. Wiese, N.F. Moller, L.N. Nielsen, K. Zilmer, J. Smidt, I. Aho, P.-. Girard, C. Pradier, E. Fontas, C. Duvivier, G. Behrens, O. Degen, C. Stefan, J. Bogner, G. Fatkenheuer, N. Chkhartishvili, P. Gargalianos, G. Xylomenos, K. Armenis, H. Sambatakou, J. Szlavik, M. Gottfredsson, F. Mulcahy, I. Yust, D. Turner, M. Burke, E. Shahar, G. Hassoun, H. Elinav, M. Haouzi, D. Elbirt, Z.M. Sthoeger, R. Esposito, I. Mazeu, C. Mussini, F. Mazzotta, A. Gabbuti, V. Vullo, M. Lichtner, M. Zaccarelli, A. Antinori, R. Acinapura, M. Plazzi, A. Lazzarin, A. Castagna, N. Gianotti, M. Galli, A. Ridolfo, B. Rozentale, V. Uzdaviniene, R. Matulionyte, T. Staub, R. Hemmer, P. Reiss, D.H. Reikvam, A. Maeland, J. Bruun, B. Knysz, J. Gasiorowski, M. Inglot, E. Bakowska, A. Grzeszczuk, M. Parczewski, K. Maciejewska, B. Aksak-Was, M. Beniowski, E. Mularska, T. Smiatacz, M. Gensing, J. Kamerys, K. Wojcik, I. Mozer-Lisewska, L. Caldeira, K. Mansinho, F. Maltez, R. Radoi, C. Oprea, A. Panteleev, O. Panteleev, T. Trofimora, I. Khromova, E. Kuzovatova, E. Borodulina, E. Vdoushkina, D. Jevtovic, J. Tomazic, J.M. Miro, M. Laguno, E. Martinez, F. Garcia, J.L. Blanco, M. Martinez-Rebollar, J. Mallolas, S. Moreno, J.M. Rodriguez, B. Clotet, A. Jou, R. Paredes, C. Tural, J. Puig, I. Bravo, M. Gutierrez, G. Mateo, M.A. Sambeat, J.M. Laporte, A. Sonnerborg, C.J. Treutiger, L. Flamholc, R. Weber, M. Cavassini, A. Calmy, H. Furrer, M. Battegay, P. Schmid, A. Kuznetsova, G. Kyselyova, B. Gazzard, A.M. Johnson, E. Simons, S. Edwards, A. Phillips, M.A. Johnson, C. Orkin, J. Weber, G. Scullard, A. Clarke, L.D. Rasmussen, V. Svedhem, J.D. Kowalska, G. Guaraldi, O. Kirk, A. Bojesen, D. Raben, D. Kristensen, K. Laut, J.F. Larsen, D. Podlekareva, B. Nykjaer, A. Cozzi-Lepri, A. Pelchen-Matthews. - In: HIV MEDICINE. - ISSN 1464-2662. - 20:4(2019), pp. 264-273. [10.1111/hiv.12711]

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

Amele S.;Peters L.;Sluzhynska M.;Yakovlev A.;Scherrer A.;Domingo P.;Gerstoft J.;Viard J. P.;Gisinger M.;Flisiak R.;Bhaghani S.;Ristola M.;Leen C.;Jablonowska E.;Wandeler G.;Stellbrink H.;Falconer K.;A. D'Arminio Monforte;Horban A.;Rockstroh J. K.;Lundgren J. D.;Mocroft A.;Losso M.;Kundro M.;Schmied B.;Zangerle R.;Karpov I.;Vassilenko A.;Mitsura V. M.;Paduto D.;Clumeck N.;De Wit S.;Delforge M.;Florence E.;Vandekerckhove L.;Hadziosmanovic V.;Begovac J.;Machala L.;Jilich D.;Sedlacek D.;Kronborg G.;Benfield T.;Katzenstein T.;Pedersen C.;Johansen I. S.;Ostergaard L.;Wiese L.;Moller N. F.;Nielsen L. N.;Zilmer K.;Smidt J.;Aho I.;Girard P. -M.;Pradier C.;Fontas E.;Duvivier C.;Behrens G.;Degen O.;Stefan C.;Bogner J.;Fatkenheuer G.;Chkhartishvili N.;Gargalianos P.;Xylomenos G.;Armenis K.;Sambatakou H.;Szlavik J.;Gottfredsson M.;Mulcahy F.;Yust I.;Turner D.;Burke M.;Shahar E.;Hassoun G.;Elinav H.;Haouzi M.;Elbirt D.;Sthoeger Z. M.;Esposito R.;Mazeu I.;Mussini C.;Mazzotta F.;Gabbuti A.;Vullo V.;Lichtner M.;Zaccarelli M.;Antinori A.;Acinapura R.;Plazzi M.;A. Lazzarin;Castagna A.;Gianotti N.;M. Galli;Ridolfo A.;Rozentale B.;Uzdaviniene V.;Matulionyte R.;Staub T.;Hemmer R.;Reiss P.;Reikvam D. H.;Maeland A.;Bruun J.;Knysz B.;Gasiorowski J.;Inglot M.;Bakowska E.;Grzeszczuk A.;Parczewski M.;Maciejewska K.;Aksak-Was B.;Beniowski M.;Mularska E.;Smiatacz T.;Gensing M.;Kamerys J.;Wojcik K.;Mozer-Lisewska I.;Caldeira L.;Mansinho K.;Maltez F.;Radoi R.;Oprea C.;Panteleev A.;Panteleev O.;Trofimora T.;Khromova I.;Kuzovatova E.;Borodulina E.;Vdoushkina E.;Jevtovic D.;Tomazic J.;Miro J. M.;Laguno M.;Martinez E.;Garcia F.;Blanco J. L.;Martinez-Rebollar M.;Mallolas J.;Moreno S.;Rodriguez J. M.;Clotet B.;Jou A.;Paredes R.;Tural C.;Puig J.;Bravo I.;Gutierrez M.;Mateo G.;Sambeat M. A.;Laporte J. M.;Sonnerborg A.;Treutiger C. J.;Flamholc L.;Weber R.;Cavassini M.;Calmy A.;Furrer H.;Battegay M.;Schmid P.;Kuznetsova A.;Kyselyova G.;Gazzard B.;Johnson A. M.;Simons E.;Edwards S.;Phillips A.;Johnson M. A.;Orkin C.;Weber J.;Scullard G.;Clarke A.;Rasmussen L. D.;Svedhem V.;Kowalska J. D.;Guaraldi G.;Kirk O.;Bojesen A.;Raben D.;Kristensen D.;Laut K.;Larsen J. F.;Podlekareva D.;Nykjaer B.;Cozzi-Lepri A.;Pelchen-Matthews A.

2019

Abstract

Objectives: The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy. Methods: Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment. Results: Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173; 81.3%), currently HCV RNA positive (3179 of 5173; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876; 43.7%), completed HCV treatment (1598 of 3876; 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876; 30.8%), and cure (629 of 3876; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001). Conclusions: In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.

Scheda breve

Scheda completa

Scheda completa (DC)

	Parole chiave
	
				continuum of care; Europe; HIV/HCV coinfection; sustained virological response; treatment
			
	Settori scientifico-disciplinari dell'articolo (sola visualizzazione)
	
				Settore MED/17 - Malattie Infettive
			
	Data di pubblicazione
	
				2019
			
	Rivista in ANCE
	
				HIV MEDICINE
			
	DOI
	
				https://dx.doi.org/10.1111/hiv.12711
			
	Tipologia
	
				Article (author)
			
	Appare nelle tipologie:
	
				01 - Articolo su periodico

File in questo prodotto:

File	Dimensione	Formato
hiv.12711.pdf accesso aperto Tipologia: Publisher's version/PDF Dimensione 266.84 kB Formato Adobe PDF Visualizza/Apri	266.84 kB	Adobe PDF	Visualizza/Apri

Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/773904

Citazioni

ND

9

9

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca